Sr. Biologist – In Vivo Obesity Research
Eli Lilly and Company
Summary
The Cardiometabolic Research unit (CMR) of Eli Lilly and Company discovers biologic, small molecule and genetic medicines for diabetes, obesity and related complications.
Job description
Role overview
The Cardiometabolic Research unit (CMR) of Eli Lilly and Company discovers biologic, small molecule and genetic medicines for diabetes, obesity and related complications.
We are seeking a skilled, motivated and versatile in vivo biologist to join the Obesity research group in Indianapolis. The successful candidate will have demonstrated experience performing in vivo studies using models and phenotyping assays relevant to research focused on obesity and diabetes. The applicant must be a task-oriented and self-motivated worker capable of conducting detailed research protocols without constant supervision, strong written and oral communication skills, and be able to work in a team-oriented environment.
Key responsibilities
- Design and run acute and chronic in vivo studies in rodent models of obesity, to evaluate targets and pathways in energy metabolism and adipose tissue.
- Perform rodent handling, dosing (including multiple routes of administration) and necropsy with tissue collection.
- Measure in vivo endpoints such as body weight, food intake, body composition, energy expenditure and glucose and insulin tolerance.
- Run molecular and biochemical assays on ex vivo samples, such as qPCR, Western blot, ELISA, etc.
- Work independently and within a team-oriented lab and cross-functional project teams.
- Keep accurate records, analyze data independently and report results in written and oral formats. Perform all work in full compliance with Lilly Research Policies and complete required training on time.
This is a full-time role with occasional weekend work, typically a few hours at a time.
Requirements
- Bachelor's degree in biology, pharmacology, physiology or a closely related field
- 2+ years of hands-on experience performing in vivo studies in rodent models
- Qualified applicants must be authorized to work in the United States on a full-time basis. Lilly will not provide support for or sponsor work authorization or visas for this role, including but not limited to F-1 CPT, F-1 OPT, F-1 STEM OPT, J-1, H-1B, TN, O-1, E-3, H-1B1, or L-1.
- Masters degree
- 2+ years hands on experience in vivo studies in rodent models of obesity or metabolic disease
- Experience in the biopharmaceutical industry
- Familiarity with ex vivo models of adipose tissue
- Experience writing IACUC protocols and knowledge of animal welfare regulations
- Ability to prioritize work across multiple projects independently and effectively
- Strong communication skills and experience presenting data to internal and external partners
Benefits
- 401(k)
- Pension
- Vacation benefits
- Medical insurance
- Dental insurance
- Vision insurance
- Prescription drug benefits
- Flexible spending accounts
- Life insurance
- Death benefits
- Time off
- Leave of absence
- Well-being benefits
- Employee assistance program
- Fitness benefits
Company overview
Eli Lilly and Company, commonly known as Lilly, is a leading American multinational pharmaceutical corporation headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company has grown into one of the world's most valuable pharmaceutical enterprises, with operations in approximately 125 countries. Lilly specializes in developing and manufacturing innovative medicines across multiple therapeutic areas, including diabetes, oncology, neuroscience, immunology, and cardiometabolic diseases. The company is renowned for its groundbreaking work in insulin production, having been the first to mass-produce insulin and later developing the first commercially available insulin product in the U.S. Lilly's current portfolio includes blockbuster medications such as Mounjaro and Zepbound (tirzepatide) for diabetes and obesity, Trulicity (dulaglutide) for type 2 diabetes, Verzenio (abemaciclib) for breast cancer, and Taltz (ixekizumab) for autoimmune conditions. With approximately 47,000 employees worldwide, Lilly maintains a strong commitment to research and development, investing heavily in scientific innovation to address some of the world's most significant health challenges. The company operates with a mission to make life better for people around the world through the discovery and delivery of innovative medicines.